Search within the Lindenbaum website

News & Insights by Lindenbaum

Lindenbaum is a litigation firm. We focus on what we do best: resolving disputes. We strategically enforce your rights by combining our expertise and experience with decisive action.

Lindenbaum is moving

Lindenbaum moves into its new offices in Amsterdam: Concertgebouwplein 13

Insights 25 September 2024

Lindenbaum is moving to its new Amsterdam offices at Concertgebouwplein 13. We look forward to meeting you there.

Read more
Lindenbaum represents Beequip’s management board

Lindenbaum represents Beequip’s management board

Insights 5 September 2024

Lindenbaum's managing partner Damiën Berkhout provided legal and governance advice to the management board of Beequip in the context of the transaction between NIBC and Apollo.

Read more
Abbvie klein

Collective action on excessive pricing of pharmaceuticals moves on to merits phase

News 5 September 2024

The Amsterdam District Court ruled that the representative organization Stichting Farma Ter Verantwoording is admissible in its collective action against pharmaceutical giant AbbVie. The case now moves on to the merits phase, in which the court will assess whether Abbvie abused its dominant position and violated human rights by charging excessive prices for its Humira medicine.

Read more
u2287224544_a_collective_action_court_case_about_the_illegal__d91fe51c-a8c6-4074-8852-5dd5df16f46b_1

Amsterdam Court of Appeal provides key decision regarding WAMCA admissibility requirements

Insights 28 August 2024

The Amsterdam Court of Appeal has provided guidance for future Dutch mass tort cases in its decision in the matter between The Privacy Collective and Oracle and Salesforce.

Read more
JIN 2024-3

Recent developments in relation to the annulment of share purchases in the Netherlands

Publications 12 August 2024

Lindenbaum partner Guido Vergouwen has published a case note in the Dutch law journal JIN on the Supreme Court case Rookie/ABC Hekwerk c.s. in relation to the annulment of share purchases.

Read more